Regeneron Pharmaceuticals, Inc. (LON:0R2M)
572.51
+33.37 (6.19%)
At close: May 12, 2025
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.03B USD in the quarter ending March 31, 2025, a decrease of -3.70%. This brings the company's revenue in the last twelve months to $14.09B, up 7.52% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.09B
Revenue Growth
+7.52%
P/S Ratio
4.22
Revenue / Employee
$932.46K
Employees
15,106
Market Cap
46.04B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
Regeneron Pharmaceuticals News
- 1 day ago - Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? - Benzinga
- 5 days ago - 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - Benzinga
- 5 days ago - Price Over Earnings Overview: Regeneron Pharmaceuticals - Benzinga
- 10 days ago - Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga
- 11 days ago - Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact - Benzinga
- 11 days ago - Regeneron ordered to face lawsuit alleging Medicare fraud over Eylea - Seeking Alpha
- 11 days ago - Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination - GlobeNewsWire
- 11 days ago - Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases - GlobeNewsWire